Compare NSSC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | MPLT |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | 1061 | 133 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | N/A |
| Metric | NSSC | MPLT |
|---|---|---|
| Price | $37.95 | $38.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $48.17 | $32.67 |
| AVG Volume (30 Days) | ★ 464.1K | 445.8K |
| Earning Date | 05-04-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.63 | N/A |
| Revenue Next Year | $10.05 | N/A |
| P/E Ratio | $54.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.27 | $12.24 |
| 52 Week High | $47.61 | $37.61 |
| Indicator | NSSC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 67.76 |
| Support Level | $37.43 | $26.20 |
| Resistance Level | $38.25 | N/A |
| Average True Range (ATR) | 1.16 | 2.59 |
| MACD | 0.23 | 0.69 |
| Stochastic Oscillator | 56.41 | 96.70 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.